CYP17A1 and prostate carcinoma: Abiraterone acetate, a notable CYP17 inhibitor, has shown efficacy in treating metastatic castration-resistant prostate cancer, demonstrating the clinical significance of targeting CYP17A1 in managing advanced stages of the disease [31,33].